The Liquid Biopsy for Cancer Diagnostics Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

DelveInsight’s, “Liquid Biopsy for Cancer Diagnostics – Competitive Landscape and Pipeline Analysis, 2023” report provides an understanding of the current competition, pipeline products, and changing market dynamics of the Liquid Biopsy for Cancer Diagnostics market in the 7 major pharmaceutical markets. The report also gives a brief competitive analysis of both the current and emerging products, to help understand the competition in the market.

Some of the key takeaways from the Liquid Biopsy for Cancer Diagnostics Pipeline Report:

• Companies across the globe are diligently working toward developing novel Liquid Biopsy for Cancer Diagnostics treatment therapies with a considerable amount of success over the years. Liquid Biopsy for Cancer Diagnostics Key players such as – Guardant360 CDx assay, Cobas EGFR Mutation Test v2, InVisionFirst, Therascreen PIK3CA test, ArcherMET, ExoDx Prostate Test, Resolution ctDx Lung assay, PlasmaSELECT 64, IvyGene DX Liver Cancer Test, LiquidHallmark test, FoundationOne Liquid, OncoBEAM, and others, are developing therapies for the Liquid Biopsy for Cancer Diagnostics treatment 

• Liquid Biopsy for Cancer Diagnostics Emerging therapies such as – CancerIntercept Detect, Exact Science’s DNA methylation-based liquid biopsy test, Parsortix, Grail’s liquid biopsy cancer test, and others are expected to have a significant impact on the Liquid Biopsy for Cancer Diagnostics market in the coming years.   
• On 2nd June 2022, GRAIL revealed a strategic partnership with AstraZeneca aimed at creating and marketing companion diagnostic (CDx) assays tailored for use alongside AstraZeneca’s treatments.

Liquid Biopsy for Cancer Diagnostics Overview

Liquid biopsy for cancer diagnostics is a non-invasive method used to detect and analyze tumor-related biomarkers, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs), in bodily fluids like blood, urine, or saliva. This technique enables the detection, monitoring, and characterization of tumors without the need for invasive procedures like tissue biopsies. 

Get a Free Sample PDF Report to know more about Liquid Biopsy for Cancer Diagnostics Pipeline Assessment- https://www.delveinsight.com/sample-request/liquid-biopsy-for-cancer-diagnostics-pipeline-insight

Liquid Biopsy for Cancer Diagnostics Pipeline Therapeutics Assessment

• Liquid Biopsy for Cancer Diagnostics Assessment by Product Type
• Liquid Biopsy for Cancer Diagnostics By Stage and Product Type
• Liquid Biopsy for Cancer Diagnostics Assessment by Route of Administration
• Liquid Biopsy for Cancer Diagnostics By Stage and Route of Administration
• Liquid Biopsy for Cancer Diagnostics Assessment by Molecule Type
• Liquid Biopsy for Cancer Diagnostics by Stage and Molecule Type

DelveInsight’s Liquid Biopsy for Cancer Diagnostics Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration 

Key Competitors in Liquid Biopsy for Cancer Diagnostics Pipeline and Market 

• Guardant Health
• Roche
• Neo Genomics
• Qiagen
• ArcherDX
• Bio-Techne
• Resolution Bioscience
• Personal Genome Diagnostics
• Laboratory for Advanced Medicine (LAM)
• Lucence Diagnostics
• Foundation Medicine Inc
• Biocept
• Sysmex Ionostics Inc
• Veridex LLC (Janssen Diagnostics)
• Biodesix
• Pathway Genomics
• Exact Sciences
• Angle Plc
• GRAIL Inc.
• NuProbe
• OncoCell MDx Inc
• Merck
• AmoyDx

Liquid Biopsy for Cancer Diagnostics Pipeline Analysis:

The Liquid Biopsy for Cancer Diagnostics pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Liquid Biopsy for Cancer Diagnostics treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liquid Biopsy for Cancer Diagnostics Treatment.
• Liquid Biopsy for Cancer Diagnostics key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Liquid Biopsy for Cancer Diagnostics Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liquid Biopsy for Cancer Diagnostics market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Liquid Biopsy for Cancer Diagnostics product details are provided in the report. Download the Liquid Biopsy for Cancer Diagnostics pipeline report to learn more about the emerging Liquid Biopsy for Cancer Diagnostics therapies

Liquid Biopsy for Cancer Diagnostics Pipeline Market Drivers

• Increasing prevalence of cancer
• Increasing preference for non-invasive procedures
• Availability of funding for liquid biopsy R&D

Liquid Biopsy for Cancer Diagnostics Pipeline Market Barriers

• Lack of harmonization
• The clinical utility of the test results
• Lack of technical knowledge and expertise

Scope of Liquid Biopsy for Cancer Diagnostics Pipeline Drug Insight    

• Coverage: Global
• Key Liquid Biopsy for Cancer Diagnostics Companies: Guardant360 CDx assay, Cobas EGFR Mutation Test v2, InVisionFirst, Therascreen PIK3CA test, ArcherMET, ExoDx Prostate Test, Resolution ctDx Lung assay, PlasmaSELECT 64, IvyGene DX Liver Cancer Test, LiquidHallmark test, FoundationOne Liquid, OncoBEAM, and others
• Key Liquid Biopsy for Cancer Diagnostics Therapies: CancerIntercept Detect, Exact Science’s DNA methylation-based liquid biopsy test, Parsortix, Grail’s liquid biopsy cancer test, and others
• Liquid Biopsy for Cancer Diagnostics Therapeutic Assessment: Liquid Biopsy for Cancer Diagnostics current marketed and Liquid Biopsy for Cancer Diagnostics emerging therapies
• Liquid Biopsy for Cancer Diagnostics Market Dynamics:  Liquid Biopsy for Cancer Diagnostics market drivers and Liquid Biopsy for Cancer Diagnostics market barriers 

Request for Sample PDF Report for Liquid Biopsy for Cancer Diagnostics Pipeline Assessment and clinical trials

Table of Contents

Download Sample PDF Report to know more about Liquid Biopsy for Cancer Diagnostics drugs and therapies

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/